Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 60 articles: HTML format Text format

Single Articles

May 2019
1. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
   Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
   Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
   PubMed     Text format    
   
   
   
2. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
   Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.
   Ann Oncol. 2019 May 2. pii: 5482567. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
3. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
   ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger.
   Ann Oncol. 2019 May 2. pii: 5482247. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   March 2019
4. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
   Treatment of Patients with Recurrent Epithelial Ovarian Cancer for Whom Platinum is Still an Option.
   Ann Oncol. 2019 Mar 18. pii: 5384492. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
5. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
   Long-term fatigue and quality of life among epithelial ovarian cancer survivors: A GINECO case/control VIVROVAIRE I Study.
   Ann Oncol. 2019 Mar 9. pii: 5372686. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   February 2019
6. LIU JF, Barry WT, Birrer M, Lee JM, et al
   Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
   Ann Oncol. 2019 Feb 7. pii: 5308594. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
7. TRIFANESCU OG, Topliceanu F, Gusoiu BA, Gales LN, et al
   24PReactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients.
   Ann Oncol. 2019;30.
   PubMed     Text format    
   
   
   December 2018
8. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
   Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
   Ann Oncol. 2018 Dec 21. pii: 5255827. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
9. WEBB PM, Na R, Weiderpass E, Adami HO, et al
   Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
   Ann Oncol. 2018 Dec 19. pii: 5253175. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   October 2018
10. LEDERMANN JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, et al
    Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed     Text format    
    
    
    July 2018
11. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2018
12. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
13. FOTOPOULOU C, Sehouli J, Mahner S, Harter P, et al
    HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
    Ann Oncol. 2018 Jun 4. pii: 5032848. doi: 10.1093.
    PubMed     Text format    
    
    
    May 2018
14. MIRZA MR, Pignata S, Ledermann JA
    Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Ann Oncol. 2018 May 10. pii: 4994787. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. MARTH C, Landoni F, Mahner S, McCormack M, et al
    Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 May 5. pii: 4993205. doi: 10.1093.
    PubMed     Text format    
    
    
    April 2018
16. RAY-COQUARD I, Morice P, Lorusso D, Prat J, et al
    Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018 Apr 25. pii: 4983953. doi: 10.1093.
    PubMed     Text format    
    
    
    
17. CREUTZBERG CL, Bosse T
    Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?
    Ann Oncol. 2018 Apr 14. pii: 4970554. doi: 10.1093.
    PubMed     Text format    
    
    
    March 2018
18. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    February 2018
19. PICCIRILLO MC, Scambia G, Bologna A, Signoriello S, et al
    Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2018 Feb 16. pii: 4864364. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
20. BIRKBAK NJ, Li Y, Pathania S, Greene-Colozzi A, et al
    Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
    Ann Oncol. 2018 Feb 14. pii: 4857262. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. KOMMOSS S, McConechy MK, Kommoss F, Leung S, et al
    Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-based Case Series.
    Ann Oncol. 2018 Feb 7. pii: 4844033. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
22. OSKAY-OZCELIK G, Alavi S, Richter R, Keller M, et al
    EXPRESSION III: Patient s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.
    Ann Oncol. 2018 Feb 5. pii: 4838337. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
23. BANERJEE S, Oza AM, Birrer MJ, Hamilton EP, et al
    Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Ann Oncol. 2018 Feb 1. pii: 4833235. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    December 2017
24. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
25. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    November 2017
26. DE BOER SM, Wortman BG, Bosse T, Powell ME, et al
    Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
    Ann Oncol. 2017 Nov 27. pii: 4668721. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
27. PROVENCHER DM, Gallagher CJ, Parulekar WR, Ledermann JA, et al
    OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Ann Oncol. 2017 Nov 23. pii: 4654091. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
28. OKTAY K, Taylan E, Rodriguez-Wallberg KA, Bedoschi G, et al
    Goserelin Does Not Preserve Ovarian Function Against Chemotherapy-Induced Damage.
    Ann Oncol. 2017 Nov 3. doi: 10.1093.
    PubMed     Text format    
    
    
    
29. LEDERMANN JA
    Front-line therapy of advanced ovarian cancer: new approaches.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
30. MONK BJ, Chan JK
    Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
31. MARTH C, Reimer D, Zeimet AG
    Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
32. BOOKMAN MA, Okamoto A, Stuart G, Yanaihara N, et al
    Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
33. BRAND AH, DiSilvestro PA, Sehouli J, Berek JS, et al
    Cytoreductive surgery for ovarian cancer: quality assessment.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
34. CHRISTIE EL, Bowtell DDL
    Acquired chemotherapy resistance in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
35. DUSKA LR, Kohn EC
    The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
36. ODUNSI K
    Immunotherapy in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
37. EISENHAUER EA
    Real-world evidence in the treatment of ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
38. PUJADE-LAURAINE E
    New treatments in ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
39. PIGNATA S, C Cecere S, Du Bois A, Harter P, et al
    Treatment of recurrent ovarian cancer.
    Ann Oncol. 2017;28.
    PubMed     Text format     Abstract available
    
    
    
40. PARK SB, Kwok JB, Asher R, Lee CK, et al
    Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
    Ann Oncol. 2017;28:2733-2740.
    PubMed     Text format     Abstract available
    
    
    October 2017
41. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    September 2017
42. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    
    
    
    
43. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
44. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available
    
    
    March 2017
45. THAKER PH, Salani R, Brady WE, Lankes HA, et al
    A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Ann Oncol. 2017;28:505-511.
    PubMed     Text format     Abstract available
    
    
    April 2016
46. DI MAIO M, Perrone F
    Lessons from clinical trials on quality of life assessment in ovarian cancer trials.
    Ann Oncol. 2016.
    PubMed     Text format    
    
    
    
47. FRIEDLANDER M, Mercieca-Bebber RL, King MT
    Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
    Ann Oncol. 2016;27 Suppl 1:i66-i71.
    PubMed     Text format     Abstract available
    
    
    
48. PUJADE-LAURAINE E, Combe P
    Recurrent ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i63-i65.
    PubMed     Text format     Abstract available
    
    
    
49. BOOKMAN MA
    Optimal primary therapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i58-i62.
    PubMed     Text format     Abstract available
    
    
    
50. LEDERMANN JA
    PARP inhibitors in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i40-i44.
    PubMed     Text format     Abstract available
    
    
    
51. KRZYSTYNIAK J, Ceppi L, Dizon DS, Birrer MJ, et al
    Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i4-i10.
    PubMed     Text format     Abstract available
    
    
    
52. MONK BJ, Minion LE, Coleman RL
    Anti-angiogenic agents in ovarian cancer: past, present, and future.
    Ann Oncol. 2016;27 Suppl 1:i33-i39.
    PubMed     Text format     Abstract available
    
    
    
53. MAHNER S, Trillsch F, Chi D, Harter P, et al
    Neoadjuvant chemotherapy in ovarian cancer revisited.
    Ann Oncol. 2016;27 Suppl 1:i30-i32.
    PubMed     Text format     Abstract available
    
    
    
54. REYNERS AK, Broekman KE, Glaudemans AW, Brouwers AH, et al
    Molecular imaging in ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i23-i29.
    PubMed     Text format     Abstract available
    
    
    
55. COUKOS G, Tanyi J, Kandalaft LE
    Opportunities in immunotherapy of ovarian cancer.
    Ann Oncol. 2016;27 Suppl 1:i11-i15.
    PubMed     Text format     Abstract available
    
    
    
56. KAYE SB
    Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Ann Oncol. 2016;27 Suppl 1:i1-i3.
    PubMed     Text format     Abstract available
    
    
    
57. POVEDA A, Romero I
    Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Ann Oncol. 2016;27 Suppl 1:i72-i73.
    PubMed     Text format    
    
    
    March 2016
58. MOSCHETTA M, George A, Kaye SB, Banerjee S, et al
    BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
59. FUJIWARA K, Monk BJ, Lhomme C, Coleman RL, et al
    Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    
    
60. MATULONIS UA, Penson RT, Domchek SM, Kaufman B, et al
    Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: